oral reversible BTK kinase inhibitor

Ph. I candidate for multiple sclerosis

from prior BTK inhibitor BIIB0685

Journal of Medicinal Chemistry


Chemical structure of molecule BIIB091 Biogen reversible BTK kinase inhibitor

5.      The Biogen reversible BTK kinase inhibitor, BIIB091, is a highly selective, phase I clinical candidate for multiple sclerosis. Irreversible BTK inhibitors have been explored and developed extensively, primarily in…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: